TY  - JOUR

T1  - Carfilzomib, lenalidomide, dexamethasone, and cyclophosphamide (KRdc) as induction therapy for transplant-eligible, newly diagnosed multiple myeloma patients (Myeloma XI+): Interim analysis of an open-label randomised controlled trial

JO  - PLOS Medicine

PY  - 2021/01/11

AU  - Jackson GH

AU  - Pawlyn C

AU  - Cairns DA

AU  - de Tute RM

AU  - Hockaday A

AU  - Collett C

AU  - Jones JR

AU  - Kishore B

AU  - Garg M

AU  - Williams CD

AU  - Karunanithi K et al

ED  - 

DO  - DOI: 10.1371/journal.pmed.1003454

PB  - Public Library of Science (PLoS)

VL  - 18

IS  - 1

Y2  - 2024/12/22

ER  -